Comment on

• MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.

  Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Bergethon K, Lauwers GY, Christensen JG, Wilner KD, Haber DA, Salgia R, Bang YJ, Clark JW, Solomon BJ, Iafrate AJ. Lennerz JK, et al. J Clin Oncol. 2011 Dec 20;29(36):4803-10. doi: 10.1200/JCO.2011.35.4928. Epub 2011 Oct 31. J Clin Oncol. 2011. PMID: 22042947 Free PMC article. Clinical Trial.
• Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer.

  Graziano F, Galluccio N, Lorenzini P, Ruzzo A, Canestrari E, D'Emidio S, Catalano V, Sisti V, Ligorio C, Andreoni F, Rulli E, Di Oto E, Fiorentini G, Zingaretti C, De Nictolis M, Cappuzzo F, Magnani M. Graziano F, et al. J Clin Oncol. 2011 Dec 20;29(36):4789-95. doi: 10.1200/JCO.2011.36.7706. Epub 2011 Oct 31. J Clin Oncol. 2011. PMID: 22042954